Related Experiment Video
Updated: May 12, 2026
12:02
Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.
Danda Chapagai1, Klaus Strebhardt2, Michael D Wyatt3
1Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, 02129, USA.
Cancer Gene Therapy
|May 16, 2025
Summary
Polo-Like Kinase 1 (PLK1) regulation involves complex conformational changes and interactions, crucial for cell cycle control and cancer drug discovery. Understanding these mechanisms offers new therapeutic strategies against cancer.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Polo-Like Kinase 1 (PLK1) is a critical regulator of mitosis, frequently overexpressed in cancers, making it a key oncology drug target.
- PLK1 features a kinase domain (KD) and a unique C-terminal polo-box domain (PBD) involved in substrate recognition, localization, and auto-inhibition.
- PLK1 regulation is influenced by post-translational modifications, phosphosubstrate binding, T210 phosphorylation, Bora protein interaction, and shifts between monomeric and dimeric forms.
Purpose of the Study:
- To review recent structural and mechanistic insights into PLK1 inhibition.
- To elucidate the temporal and spatial requirements for PLK1 activation and regulation.
- To discuss the implications of PLK1 conformational regulation for cell cycle function and cancer drug discovery.
Main Methods:
- Literature review of recent studies on PLK1 structure, function, and regulation.
- Analysis of research on post-translational modifications and domain-domain interactions within PLK1.
- Examination of studies investigating PLK1 oligomerization and its role in cell cycle control.
Main Results:
- PLK1 activation involves transitioning to an open conformation, overcoming autoinhibition through events like T210 phosphorylation and Bora interaction.
- PLK1 exists in dynamic monomeric and dimeric forms, influencing its activity and regulation during the cell cycle.
- Structural and mechanistic insights reveal complex regulatory networks governing PLK1 activity and localization.
Conclusions:
- Understanding PLK1's conformational dynamics and regulatory mechanisms is vital for developing effective cancer therapies.
- Targeting PLK1's regulatory pathways offers significant potential for novel oncology drug development.
- The intricate regulation of PLK1 highlights its central role in cell cycle progression and cancer pathogenesis.
Related Concept Videos
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...